Nail toxicity after treatment with docetaxel: A prospective analysis in patients with advanced non-small cell lung cancer

Japanese Journal of Clinical Oncology

Volumn 37, Issue 6, 2007, Pages 424-428

  Hong, Junshik ^a   Park, Se Hoon ^a   Choi, Soo Jin ^a   Lee, Seok Ho ^a   Lee, Kyu Chan ^a   Lee, Jae Ik ^a   Kyung, Sun Young ^a   An, Chang Hyeok ^a   Lee, Sang Pyo ^a   Park, Jeong Woong ^a   Jeong, Sung Hwan ^a   Nam, Eunmi ^a   Bang, Soo Mee ^a   Cho, Eun Kyung ^a   Shin, Dong Bok ^a   Lee, Jae Hoon ^a  

^a Gachon University   (South Korea)

Author keywords

Chemotherapy; Docetaxel; Nail changes

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; NARCOTIC ANALGESIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEBRIDEMENT; DISEASE SEVERITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAIL; NAIL DISEASE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; HUMANS; PROSPECTIVE STUDIES; TAXOIDS;

EID: 34547889894     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym042     Document Type: Article

References (32)

1. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): A semisynthetic analogue of taxol. J Natl Cancer Inst 1991;83:288-91.
2. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993;53:1037-42.
3. Camps C, Massuti B, Jimenez A, Maestu I, Gomez RG, Isla D, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: A Spanish Lung Cancer Group trial. Ann Oncol 2006;17:467-72.
4. Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2005;16:90-6.
5. Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004;91:1996-2004.
6. Lai CL, Tsai CM, Chiu CH, Wang GS, Su WJ, Chen YM, et al. Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer. Jpn J Clin Oncol 2005;35:700-6.
7. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 2005;23:8389-95.
8. Park SH, Choi SJ, Kyung SY, An CH, Lee SP, Park JW, et al. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer. Cancer 2007;109:732-40.
9. Posner MR. Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs 2001;12(Suppl 1):S21-4.
10. Rigas JR, Dragnev KH, Bubis JA. Docetaxel in the treatment of esophageal cancer. Semin Oncol 2005;32(Suppl 4):S39-51.
11. Philip PA. Experience with docetaxel in the treatment of gastric cancer. Semin Oncol 2005;32(Suppl 4):S24-38.
12. Lyseng-Williamson KA, Fenton C. Docetaxel: A review of its use in metastatic breast cancer. Drugs 2005;65:2513-31.
13. Belani CP. Optimizing chemotherapy for advanced non-small cell lung cancer: Focus on docetaxel. Lung Cancer 2005;50(Suppl 2):S3-8.
14. Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: The Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004;22:254-61.
15. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003;21:3016-24.
16. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-62.
17. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 2000;18:2095-103.
18. Crown J, O'Leary M. The taxanes: An update. Lancet 2000;355:1176-8.
19. Hainsworth JD, Burris HA, 3rd, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998;16:2164-8.
20. Briasoulis E, Karavasilis V, Anastasopoulos D, Tzamakou E, Fountzilas G, Rammou D, et al. Weekly docetaxel in minimally pretreated cancer patients: A dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 1999;10:701-6.
21. Engels FK, Sparreboom A, Mathot RA, Verweij J. Potential for improvement of docetaxel-based chemotherapy: A pharmacological review. Br J Cancer 2005;93:173-7.
22. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
23. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004;15:1358-65.
24. Piraccini BM, Tosti A. Drug-induced nail disorders: Incidence, management and prognosis. Drug Saf 1999;21:187-201.
25. Minisini AM, Tosti A, Sobrero AF, Mansutti M, Piraccini BM, Sacco C, et al. Taxane-induced nail changes: Incidence, clinical presentation and outcome. Ann Oncol 2003;14:333-7.
26. Scotte F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005;23:4424-9.
27. Childress J, Lokich J. Cutaneous hand and foot toxicity associated with cancer chemotherapy. Am J Clin Oncol 2003;26:435-6.
28. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000;1:225-34.
29. Smith IE, O'Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-43.
30. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002;20:1335-43.
31. Luedke DW, Einhorn L, Omura GA, Sarma RR, Bartolucci AA, Birch R, et al. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: A Southeastern Cancer Study Group Trial. J Clin Oncol 1990;8:886-91.
32. Lilenbaum RC, Langenberg P, Dickersin K. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: A meta-analysis of response, toxicity, and survival. Cancer 1998;82:116-26.